pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$ALMSALUMIS INC.

$ALMS6.8500-4.99%
South San Francisco, CA, USupdated 1d ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
2
marketed
0
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(2)

pipeline depth2 products
Phase 2: 1Phase 3: 1
1Phase 21Phase 3
Phase 3
envudeucitinib
Plaque Psoriasis (Psoriasis Vulgaris)
Phase 2
lonigutamab
Graves' Ophthalmopathy

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Aug 12, 2026
earnings
$ALMS6.8500-4.99%
2mo ago
ALUMIS INC. earnings
ALUMIS INC.
→
view all catalysts →

Active trials

  • phase3A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasiscompletedn=912
  • phase3A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001completedn=862
  • phase2Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosusactive not recruitingn=408
  • phase3Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasisactive not recruitingn=1,680
  • phase2Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasisactive not recruitingn=165
  • phase1An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005completedn=135
  • phase1An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001completedn=52
  • phase1An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Functioncompletedn=16
🐶 Hiring Signal
6 open roles at ALUMIS INC. →

Where ALUMIS INC. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaImmunology & Inflammation 6
departmentMedical Affairs 6

News

  • Trending: Top biopharma disciplines with jobs live now
    From engineering to science/R&D, these top seven biopharma disciplines each have hundreds, and in one case over 1,000, positions posted on BioSpace.
    biospace · 17d ago
  • 11 companies hiring in California now
    Looking for a biopharma job in California? Check out the BioSpace list of 11 companies hiring life sciences professionals like you.
    biospace · 24d ago
  • Opinion: How the Amish think about vaccines, health care costs, and much more
    There may be nearly 2 million Amish Americans by 2075. That has large public health implications.
    stat · 4mo ago
identifiers
ticker
$ALMS
SEC CIK
0001847367
country
US
source
sec_tickers
top tags
Immunology1Ophthalmology1
mentioned in
3news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 7m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?